Bavarian Nordic Raises 2026 Revenue Forecast on Surge in Travel…

Event summary

Bavarian Nordic upgraded its 2026 revenue guidance to DKK 6.1 billion from DKK 5.7 billion, driven by stronger-than-expected Travel Health sales.
Travel Health revenue now expected to reach DKK 3.4 billion, up from DKK 3.0 billion, due to increased rabies vaccine demand in the U.S.
EBITDA margin forecast raised to 32% from 30%, while Public Preparedness revenue remains unchanged at DKK 2.5 billion.
The upgrade follows higher rabies vaccine sales due to increased animal rabies activity and human exposure in the U.S.

The big picture

Bavarian Nordic's upgraded guidance reflects a broader trend of increasing demand for travel and public health vaccines, particularly in response to emerging health threats. The company's ability to capitalize on this demand highlights its strategic focus on travel health, a segment that has seen growing importance in the post-pandemic era. The raise in EBITDA margin also signals improved operational efficiency, which could attract further investor interest.

What we're watching

Market Demand: Whether the surge in rabies vaccine demand in the U.S. will be sustained or if it is a temporary spike.
Execution Risk: How Bavarian Nordic will manage the increased production and distribution demands for its Travel Health products.
Competitive Dynamics: The pace at which competitors may respond to Bavarian Nordic's strong performance in the Travel Health segment.